GenSight Biologics S.A
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV… Read more
GenSight Biologics S.A (GSGTF) - Net Assets
Latest net assets as of June 2025: $-32.11 Million USD
Based on the latest financial reports, GenSight Biologics S.A (GSGTF) has net assets worth $-32.11 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.35 Million) and total liabilities ($39.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-32.11 Million |
| % of Total Assets | -436.76% |
| Annual Growth Rate | N/A |
| 5-Year Change | -330.74% |
| 10-Year Change | -191.79% |
| Growth Volatility | 97.03 |
GenSight Biologics S.A - Net Assets Trend (2012–2024)
This chart illustrates how GenSight Biologics S.A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GenSight Biologics S.A (2012–2024)
The table below shows the annual net assets of GenSight Biologics S.A from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-26.92 Million | +12.32% |
| 2023-12-31 | $-30.70 Million | -100.94% |
| 2022-12-31 | $-15.28 Million | -195.55% |
| 2021-12-31 | $15.99 Million | +37.05% |
| 2020-12-31 | $11.67 Million | -0.67% |
| 2019-12-31 | $11.75 Million | -50.79% |
| 2018-12-31 | $23.87 Million | -56.60% |
| 2017-12-31 | $55.00 Million | +3.10% |
| 2016-12-31 | $53.34 Million | +81.88% |
| 2015-12-31 | $29.33 Million | +177.21% |
| 2014-12-31 | $10.58 Million | -37.64% |
| 2013-12-31 | $16.97 Million | +25623.92% |
| 2012-12-31 | $-66.47K | -- |
Equity Component Analysis
This analysis shows how different components contribute to GenSight Biologics S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1389653100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.12 Million | % |
| Other Comprehensive Income | $-222.64 Million | % |
| Other Components | $206.61 Million | % |
| Total Equity | $-26.92 Million | 100.00% |
GenSight Biologics S.A Competitors by Market Cap
The table below lists competitors of GenSight Biologics S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Genesis Scale Holdings Limited
F:92N0
|
$20.79 Million |
|
Damsan JSC
VN:ADS
|
$20.81 Million |
|
Fiducial Real Estate SA
PA:ORIA
|
$20.81 Million |
|
Finebesteel
KO:133820
|
$20.82 Million |
|
Companhiade Eletricidade do Estado da Bahia - COELBA
SA:CEEB3
|
$20.78 Million |
|
Aspire Mining Ltd
AU:AKM
|
$20.78 Million |
|
Manolete Partners Plc
PINK:MANOF
|
$20.77 Million |
|
TAO Synergies Inc.
NASDAQ:TAOX
|
$20.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GenSight Biologics S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -30,668,000 to -26,920,000, a change of 3,748,000.
- Net loss of 14,001,000 reduced equity.
- Share repurchases of 27,000 reduced equity.
- New share issuances of 16,742,000 increased equity.
- Other comprehensive income decreased equity by 25,591,999.
- Other factors increased equity by 26,625,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.00 Million | -52.01% |
| Share Repurchases | $27.00K | -0.1% |
| Share Issuances | $16.74 Million | +62.19% |
| Other Comprehensive Income | $-25.59 Million | -95.07% |
| Other Changes | $26.63 Million | +98.91% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares GenSight Biologics S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $1.94 | $0.24 | x |
| 2014-12-31 | $1.19 | $0.24 | x |
| 2015-12-31 | $2.61 | $0.24 | x |
| 2016-12-31 | $3.28 | $0.24 | x |
| 2017-12-31 | $2.51 | $0.24 | x |
| 2018-12-31 | $0.98 | $0.24 | x |
| 2019-12-31 | $0.41 | $0.24 | x |
| 2020-12-31 | $0.33 | $0.24 | x |
| 2021-12-31 | $0.35 | $0.24 | x |
| 2022-12-31 | $-0.33 | $0.24 | x |
| 2023-12-31 | $-0.63 | $0.24 | x |
| 2024-12-31 | $-0.33 | $0.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GenSight Biologics S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -933.40%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-90.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -16.29% | -304.13% | 0.05x | 1.11x | $-4.46 Million |
| 2014 | -63.06% | -604.99% | 0.07x | 1.40x | $-7.73 Million |
| 2015 | -46.56% | -383.53% | 0.10x | 1.24x | $-16.59 Million |
| 2016 | -41.40% | -735.81% | 0.05x | 1.11x | $-27.42 Million |
| 2017 | -43.84% | -651.32% | 0.06x | 1.13x | $-29.61 Million |
| 2018 | -140.15% | -769.74% | 0.12x | 1.55x | $-35.84 Million |
| 2019 | -261.45% | -4387.14% | 0.02x | 2.77x | $-31.88 Million |
| 2020 | -289.52% | -774.15% | 0.09x | 4.03x | $-35.19 Million |
| 2021 | -178.97% | -542.40% | 0.09x | 3.54x | $-30.22 Million |
| 2022 | 0.00% | -1069.87% | 0.10x | 0.00x | $-26.10 Million |
| 2023 | 0.00% | -2069.46% | 0.14x | 0.00x | $-23.15 Million |
| 2024 | 0.00% | -933.40% | 0.14x | 0.00x | $-11.31 Million |
Industry Comparison
This section compares GenSight Biologics S.A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GenSight Biologics S.A (GSGTF) | $-32.11 Million | -16.29% | N/A | $20.78 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |